<DOC>
	<DOCNO>NCT02323126</DOCNO>
	<brief_summary>To determine efficacy safety Nivolumab combination EGF816 Nivolumab combination INC280 previously treat NSCLC patient</brief_summary>
	<brief_title>Study Efficacy Safety Nivolumab Combination With EGF816 Nivolumab Combination With INC280 Patients With Previously Treated Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This study two arm : Arm 1 ( EGF816 + nivolumab ) currently close new enrollment . Arm 2 ( INC280 + nivolumab ) open enrol plan .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written informed consent must obtain prior screen procedure Presence least one measurable lesion accord RECIST v.1.1 ECOG performance status â‰¤ 2 Patients histologically document locally advanced , recurrent and/or metastatic NSCLC Tumor tissue determination and/or confirmation genetic prerequisite ( i.e . EGFR T790M positivity post progression EGFR TKI Group 1 ; cMet status Group 2 ) must provide analysis Group 1 patient : Patients EGFR T790M NSCLC ( adenocarcinoma ) Documented progression disease accord RECIST v1.1 follow primary standard care ( e.g . erlotinib , gefitinib ) Group 2 patient : Patients EGFR wildtype NSCLC Documented progression disease accord RECIST v1.1 follow standard care ( e.g . platinum doublet ) . Patients receive one prior line EGFR TKI therapy1 ( applies Group 1 ) Previous treatment cMET inhibitor HGFtargeting therapy ( applies Group 2 ) Patients brain metastasis . However , radiation therapy and/or surgery complete serial evaluation CT ( contrast enhancement ) MRI minimum one month demonstrate disease stable patient remain must need treatment steroid Patients require emergent use systemic steroid , chronic use prednisone ( great 10mg equivalent steroid dose daily ) emergent surgery and/or radiotherapy . History allergy hypersensitivity nivolumab component Patients know suspected , current past history , autoimmune disease . Patients type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll Patients condition require chronic systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day treatment start . Inhaled topical steroid , adrenal replacement steroid dose &gt; 10 mg daily prednisone equivalent , permit absence active autoimmune disease Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Any positive test hepatitis B virus hepatitis C virus indicate acute chronic infection Patients interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity Patients interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity Prior therapy : Patients treat prior PD1 PDL1 agent Patients previously receive agent target cMET and/or EGFR T790M Note : Previous treatment afatinib may allowable discussion Novartis Investigator . Patients follow laboratory abnormality : Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L Hemoglobin ( Hgb ) &lt; 9 g/dL Platelets &lt; 100 x 109/L Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) . For patient Gilbert 's syndrome total bilirubin &gt; 2.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 x ULN Serum creatinine &gt; 1.5 x ULN and/or measure calculated creatinine clearance &lt; 75 % LLN For patient screen Group 2 , asymptomatic serum amylase &gt; CTCAE Grade 2 ( 1.52.0 x ULN ) . Patients Grade 1 Grade 2 serum amylase begin study must confirm sign symptom suggest pancreatitis pancreatic injury ( e.g. , elevated Pamylase , abnormal imaging finding pancreas , etc . ) For patient screen Group 2 : Serum lipase &gt; ULN Female patient either pregnant nursing . Women child bear potential refuse able use highly effective method contraception define study protocol . Sexually active male unless use condom intercourse take drug 31 week last dose study treatment . Other protocolrelated inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non small cell lung cancer ,</keyword>
	<keyword>NSCLC ,</keyword>
	<keyword>EGFR-mutated ,</keyword>
	<keyword>EGF816 ,</keyword>
	<keyword>INC280 ,</keyword>
	<keyword>Nivolumab ,</keyword>
	<keyword>EGFR-T790M NSCLC ,</keyword>
	<keyword>EGFR wild-type ( wt ) ,</keyword>
	<keyword>cMET positive NSCLC ,</keyword>
	<keyword>cMET negative NSCLC</keyword>
</DOC>